Target intelligence / Profile preview

Period circadian regulator 1 (PER1)

Target
PER1
Molecular classification
Transcription factor, Clock gene/protein, PAS-domain protein
01

Overview

Period circadian regulator 1 (PER1) is a core transcriptional regulator of the mammalian circadian clock, orchestrating cell autonomous 24-hour oscillations in gene expression, especially in the suprachiasmatic nucleus and peripheral tissues. PER1 protein functions in a feedback loop: activated by the CLOCK/BMAL1 complex, it heterodimerizes with CRY proteins and translocates to the nucleus, where it inhibits its own transcription and other clock gene expression, ensuring rhythmic cycles. Post-translational modifications, like CK1ε/δ phosphorylation and ubiquitin-mediated proteasomal degradation, fine-tune its abundance and timing. PER1 is implicated as a tumor suppressor, with loss or downregulation associated with proliferation, impaired apoptosis, altered DNA repair, and therapy resistance in various cancers. Additional roles include mediating metabolic responses to toxins, modulating glucocorticoid signaling, and influencing neurobehavioral phenotypes through clock gene regulation.

Other names
Period circadian protein homolog 1Period circadian clock 1Period homolog 1KIAA0482RIGUIhPER1Circadian clock protein PERIOD 1Circadian pacemaker protein RiguiCircadian pacemaker protein RIGUI
02

Mechanism of action

Mechanism of action for drugs targeting PER1 would involve chronotherapeutics (modulation of PER1 expression or function to restore normal circadian gene expression cycles, enhance apoptosis, and suppress tumor growth). This can include epigenetic modulation (altering promoter methylation to restore PER1 expression, especially in cancer), protein-protein interaction disruption (targeting feedback inhibition mechanisms, e.g., PER/CRY interaction with CLOCK-BMAL1), or modulation of metabolic regulators (e.g., interaction with HNF-1α to regulate CYP2E1-mediated toxin metabolism).

03

Biological functions

Circadian rhythm regulationTranscriptional regulationCell cycle regulationMetabolic regulationDNA damage responseGlucocorticoid response modulation
04

Disease associations

Cancer (breast, prostate, colorectal, gastric, skin cancer)Neuropsychiatric disorders (bipolar disorder, autism spectrum disorder, ADHD, sleep/mood disturbance)Peripheral/metabolic disorders (sleep apnea, metabolic syndrome, liver toxicity)Circadian clock disruptions (sleep disorders, advanced sleep phase syndrome)
05

Safety considerations

Disruption can affect systemic circadian regulation, leading to sleep, metabolic, or immune disturbancesPotential off-target effects due to widespread PER1 expression and systemic regulatory functionsTherapeutic modulation may alter cell cycle and apoptosis, which could unintentionally promote oncogenesis or suppress normal cell turnover if not tightly regulated
06

Biomarkers

PER1 expression/methylation status (in cancer, reduced expression or promoter methylation are used as tumor suppressor biomarkers)PER1 genetic variants (potential marker for neuropsychiatric and sleep disorders, though population significance is debated)PER1 rhythmicity in peripheral tissues can serve as a biomarker for circadian function

Beyond the preview

Go deeper on Period circadian regulator 1 (PER1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Period circadian regulator 1 (PER1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call